heparin

(redirected from Sodium heparin)
Also found in: Dictionary, Thesaurus, Encyclopedia.

heparin

 [hep´ah-rin]
1. an acid mucopolysaccharide present in many tissues, especially the liver and lungs, and having potent anticoagulant properties. It also has lipotrophic properties, promoting transfer of fat from blood to the fat depots by activation of the enzyme lipoprotein lipase.
2. a mixture of active principles capable of prolonging blood clotting time, obtained from domestic animals; used in the prophylaxis and treatment of clotting disorders, such as thrombophlebitis, pulmonary embolism, disseminated intravascular coagulation, acute myocardial infarction, or stroke syndrome, and to prevent clotting during extracorporeal circulation, blood transfusion, and blood sampling.
heparin lock a type of intermittent intravenous device for the administration of heparin. It does not require a continuous flow of fluids; the intravenous fluid flow can be disconnected and the heparin lock filled with a heparin solution that maintains patency of the needle.
Two types of heparin or saline lock sets. From Lammon et al., 1995.

hep·a·rin

(hep'ă-rin),
An anticoagulant principle that is a component of various tissues (especially liver and lung) and mast cells in humans and several mammalian species; its principal and active constituent is a glycosaminoglycan composed of d-glucuronic acid and d-glucosamine, both sulfated, in 1,4-α linkage, of molecular weight between 6,000 and 20,000. In conjunction with a serum protein cofactor (the so-called heparin cofactor), heparin acts as an antithrombin and an antiprothrombin. Synthetic preparations are commonly used in therapeutic anticoagulation. It also enhances activity of "clearing factors" (lipoprotein lipases).
Synonym(s): heparinic acid

heparin

/hep·a·rin/ (hep´ah-rin) a sulfated glycosaminoglycan of mixed composition, released by mast cells and by blood basophils in many tissues, especially the liver and lungs, and having potent anticoagulant properties. It also has lipotrophic properties, promoting transfer of fat from blood to the fat depots by activation of lipoprotein lipase. It is used as the calcium or sodium salt in the prophylaxis and treatment of disorders in which there is excessive or undesirable clotting and to prevent clotting during extracorporeal circulation, blood transfusion, and blood sampling.

heparin

(hĕp′ər-ĭn)
n.
An acidic glycosaminoglycan found especially in lung and liver tissue and having the ability to slow the clotting of blood, used as a drug in the treatment of thrombosis.

heparin

[hep′ərin]
Etymology: Gk, hēpar, liver
a naturally occurring mucopolysaccharide that acts in the body as an antithrombin factor to prevent intravascular clotting. The substance is produced by basophils and mast cells, which are found in large numbers in the connective tissue surrounding capillaries, particularly in the lungs and liver. In the form of sodium salt, heparin is used therapeutically as an anticoagulant. See also heparin sodium.

heparin

Hematology A sulfated glycosaminoglycan anticoagulant that inhibits activated factors IXa, Xa, XIa, XIIa and thrombin, ↓ local anti-thrombin-III, promoting its inactivation by neutrophil elastase; interaction of heparin with endothelial cells results in displacement of platelet factor 4, which inactivates heparin Indications Thromboembolism, CAD, post acute MI, PTE Monitoring Titrate heparin so that aPTT is 1.5-2.0-fold normal Side effects Hemorrhage, thrombocytopenia, osteoporosis, skin necrosis, alopecia, hypersensitivity, hypoaldosteronism. See Low-molecular weight heparin.

hep·a·rin

(hep'ăr-in)
An anticoagulant that is a component of various tissues (especially liver and lung) and mast cells. Its principal active constituent is a glycosaminoglycan composed of d-glucuronic acid and d-glucosamine. In conjunction with a serum protein cofactor (the so-called heparin cofactor), heparin acts as an antithrombin and an antiprothrombin by preventing platelet agglutination and consequent thrombus formation.

heparin

A complex polysaccharide organic acid found mainly in lung and liver tissue. Heparin is thought to bind to THROMBIN and antithrombin in plasma thereby assisting in their combination and interfering with the cascade of reactions that end in blood clotting (coagulation). From the Greek hepar , the liver. The drug is on the WHO official list. Heparin is widely used as an anticoagulant under brand names such as Calciparine, Canusal, Hepsal, Monoparin and Multiparin. See also LOW MOLECULAR WEIGHT HEPARIN.

heparin

a mucopolysaccharide molecule produced in the liver and some white blood-cells that acts as an anticoagulant, inhibiting the transformation of prothrombin to thrombin, a vital stage in BLOOD CLOTTING.

Heparin

An organic acid that occurs naturally in the body and prevents blood clots. Heparin is also made synthetically and can be given as a treatment when required.

heparin

an acid mucopolysaccharide present in many tissues, especially the liver and lungs, and having potent anticoagulant properties. It also has lipotrophic properties, promoting transfer of fat from blood to the fat depots by activation of lipoprotein lipase. Also, a mixture of active principles capable of prolonging blood clotting time, obtained from domestic animals; used in the prophylaxis and treatment of disorders in which there is excessive or undesirable clotting and as a preservative for blood specimens.
References in periodicals archive ?
As part of a blinded comparison of alteplase and ACR on clotted specimens, the mitotic index (MI) was calculated for a series of 40 standard and 40 high-resolution cultured specimens, including 20 each treated with alteplase or ACR, 20 sodium heparin and 20 clot-tube specimens (Table 2).
All FISH studies were successful, regardless of whether the interphase cells were isolated from the clotted, sodium heparin, or thrombolytic-treated specimens.
15) In a study comparing dried with liquid sodium heparin at exactly the same concentration (33 IU/mL blood), however, there was no difference in measured pH, pC[O.
The inclusion of electrolytes in the test repertoire excludes the use of sodium heparin in favor of lithium heparin.
None of the various blood components (bilirubin, human serum albumin, hemoglobin, triglycerides, fibrinogen, and alkaline phosphatase) or cardiac-related drugs (abciximab, acetaminophen, allopurinol, ambroxol, ampicillin, ascorbic acid, aspirin, atenolol, caffeine, captopril, cinnarizine, cocaine, diclofenac, digoxin, dopamine, erythromycin, furosemide, ibuprofen, low-molecular weight heparin, methyldopa, nifedipine, nitrofurantoin, nystatin, oxytetracycline, phenytoin, propranolol, quinidine, sodium heparin, theophylline, trimethoprim, and verapamil) tested interfered with the assay; all results were within 5% of controls.
The 3-mL plastic syringes (Becton Dickinson) were preloaded with 10 mL/L of either isotonic saline or porcine intestine-derived sodium heparin (Elkins-Sinn, Cherry Hill, NJ) diluted in saline and tested at 300 IU/L final concentration.
Plasma samples were prepared from blood collected from 24 apparently healthy volunteers and from 58 patients receiving a continuous infusion of sodium heparin (Thromboliquine).
Plasmas from patients receiving a continuous infusion of sodium heparin, collected as described above, were pooled.
We also learned that the patient's catheter was routinely filled with 5000 USP units/mL sodium heparin between dialysis procedures.
To determine whether sodium heparin was responsible for this perplexing set of values, we diluted routine patients' serum with 0-300 mL/L of a sodium heparin solution (5000 USP units/mL; Elkins-Sinn, Cherry Hill, NJ).